Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-11-2014 | Original Paper

Rates and Predictors of Adherence to Psychotropic Medications in Children with Autism Spectrum Disorders

Auteurs: Sarah L. Logan, Laura Carpenter, R. Scott Leslie, Kelly S. Hunt, Elizabeth Garrett-Mayer, Jane Charles, Joyce S. Nicholas

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 11/2014

Abstract

Medication adherence in children is poor, particularly among those with chronic or mental health disorders. However, adherence has not been fully assessed in autism spectrum disorders (ASDs). The validated proportion of days covered method was used to quantify adherence to psychotropic medication in Medicaid-eligible children who met diagnostic criteria for ASD between 2000 and 2008 (N = 628). Among children prescribed attention deficit hyperactivity disorder (ADHD) medications, antidepressants, or antipsychotics, 44, 40 and 52 % were adherent respectively. Aggressive behaviors and abnormalities in eating, drinking, and/or sleeping, co-occurring ADHD, and the Medication Regimen Complexity Index were the most significant predictors of adherence rather than demographics or core deficits of ASD. Identifying barriers to adherence in ASD may ultimately lead to improved treatment outcomes.

vorige artikel Are We Under-Estimating the Association Between Autism Symptoms?: The Importance of Considering Simultaneous Selection When Using Samples of Individuals Who Meet Diagnostic Criteria for an Autism Spectrum Disorder

volgende artikel Autistic Traits in Couple Dyads as a Predictor of Anxiety Spectrum Symptoms

Alleen toegankelijk voor geautoriseerde gebruikers

Akincigil, A., Bowblis, J., et al. (2007). Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Medical Care, 45(4), 363–369. PubMedPubMedCentralCrossRef

Allison, P. (2001). Logistic regression using the SAS system: Theory and application (p. 48). Cary: Wiley-SAS.

Aman, M. G., Lam, K. S. L., et al. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15(1), 116–126. PubMedCrossRef

American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorder, fourth edition, text revision. Washington, DC: American Psychiatric Association.

Arney, J., Street, R. J., et al. (2012). Factors shaping physicians’ willingness to accomodate medication requests. Evaluations & the Health Professions [Epub ahead of print].

Bilder, D., Pinborough-Zimmerman, J., Miller, J., & McMahon, W. (2009). Prenatal, perinatal, and neonatal factors associated with autism spectrum disorders. Pediatrics, 123(5), 1293–1300. PubMedCrossRef

Bunch, B. (2008). South Carolina Department of Commerce. Division of Research. Developing a rural definition, analysis of South Carolina counties. http://sccommerce.com/sites/default/files/document_directory/Rural_Definition_Developing_a_Rural_Definition_for_South_Carolina_Analysis_of_South_Carolina_Counties_2008.pdf.

Bussing, R., et al. (2003). Parental explanatory models of ADHD: Gender and cultural variation. Social Psychiatry and Psychiatric Epidemiology, 38(10), 563–575. PubMedCrossRef

Canas, F., Alptekin, K., et al. (2013). Improving treatment adherence in your patients with Schizophrenia: The STAY initiative. Clinical Drug Investigation, 33(2), 97–107.

CDC. (2012). Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Morbidity and Mortality Weekly Report, 61(SS03), 1–19.

Census, US. (2013). US Office of Management and Budget. http://www.census.gov/population/www/estimates/metroarea.html. Accessed September 03, 2013.

Chacko, A., Neworn, J., et al. (2010). Improving medication adherence in chronic pediatric health conditions: A focus on ADHD in youth. Current Pharmaceutical Design, 16, 2416–2423. PubMedCrossRef

Chavira, D., et al. (2003). Parental opinions regarding treatment for social anxiety disorder in youth. Journal of Developmental and Behavioral, 24(5), 315–322.

Ciechanowski, P., Katon, W., et al. (2000). Depression and diabetes: Impact of depressives symptoms on adherence, function, and costs. Archives of Internal Medicine, 27, 3278–3285. CrossRef

CMS. (2011). New medicare part D patient safety report—Antiret-roviral adherence. Baltimore, Maryland: Department of Health and Human Services. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/MemoPtSafetyRepor_122911.pdf.

Courrege, D. (2012). Charleston special education review turns up problems, commendations. The Post and Courier. Charleston, SC. http://www.postandcourier.com/article/20120407/UNKNOWN/120409293. Accessed 03 September 2013.

Coury, D. (2011). Very little high-quality evidence to support most medications for children with autism spectrum disorders. The Journal of Pediatrics, 159(5), 872–873. PubMedCrossRef

Coury, D., Anagnostou, E., et al. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(S69), S69–S76. PubMedCrossRef

Cramer, J., et al. (2007). Medication compliance and persistence: terminology and definitions. Value in Health. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Medication Compliance and Persistence Work Group, 11, 44–47.

Dawson, G. (2013). Dramatic increase in autism prevalence parallels explosion of research into its biology and causes. Archives of General Psychiatry, 70(1), 9–10. doi: 10.1001/jamapsychiatry.2013.488.

Dean, A. J., Wragg, J., et al. (2011). Predictors of medication adherence in children receiving psychotropic medication. Journal of Paediatrics and Child Health, 47(6), 350–355. PubMedCrossRef

Dilorio, C., Yeager, K., Shafer, P. O., Letz, R., Henry, T., Schomer, D. L., et al. (2003). The epilepsy medication and treatment complexity index: Reliability and validity testing. Journal of Neuroscience Nursing, 35(3), 155–162. CrossRef

Donohue, J. M., Berndt, E. R., et al. (2004). Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care, 42(12), 1176–1185. PubMedCrossRef

Donohue, J. M., Cevasco, M., et al. (2007). A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine, 357(7), 673–681. PubMedCrossRef

dosReis, S., Zito, J. M., et al. (2005). Multiple psychotropic medication use for youths: A two-state comparison. Journal of Child and Adolescent Psychopharmacology, 15(1), 68–77. PubMedCrossRef

Dove, D., Warren, Z., et al. (2012). Medications for adolescents and young adults with autism spectrum disorders: A systematic review. Pediatrics, 130(4), 717–726. PubMedPubMedCentralCrossRef

Drotar, D., Neff-Greenley, R., et al. (2007). Adherence to pharmacological treatment for juvenile bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(7), 831–839. PubMedCrossRef

Durkin, M., Maenner, M., Meaney, F., Levy, S. E., DiGuiseppi, C., Nicholas, J. S., et al. (2010). Socioeconomic inequality in the prevalence of autism spectrum disorder: Evidence from a US cross-sectional study. PLoS ONE, e11511.

Durkin, M. S., Maenner, M., Newschaffer, C. J., Lee, L. C., Cunniff, C. M., Daniels, J. L., et al. (2008). Advanced parental age and the risk of autism spectrum disorder. American Journal of Epidemiology, 168(11), 1268–1276. PubMedPubMedCentralCrossRef

Esbensen, A., Greenberg, J., et al. (2009). A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39(9), 1339–1349.

Farley, J., Hansen, R., et al. (2012). Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. The Primary Care Companion to CNS Disorders. doi: 10.4088/PCC.11m01324.

Faught, E., Duh, M., et al. (2008). Nonadherence to antiepileptic drugs and increased mortality findings from the RANSOM Study. Neurology, 17(20), 1572–1578. CrossRef

FDA. (2006). NDA 20‐272 / S‐036, 20‐588 / S‐024, 21‐444 / S‐008: Final Agreed‐Upon Labeling. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021444s008s015,020588s024s028s029,020272s036s041lbl.pdf.

FDA. (2008). New or modified indication. Label and Approval History of Strattera (Atomoxetine Hydrochloride). Letter 5/2008 by Lilly. http://fdazilla.com/drugs/appdoc/19799.

FDA. (2009). New indication approval for Abilify (aripiprazole). Supplemental Letter. NDA 021436/S‐027. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021436s027ltr.pdf.

Fontanella, C., Bridge, J., et al. (2011). Factors associated with antidepressant adherence for Medicaid-eligible enrolled children and adolescents. Annals of Pharmacotherapy, 45, 898–909. PubMedCrossRef

Friedman, L., Furberg, C., et al. (2010). Fundamentals of clinical trials. New York, Heidelberg: Springer, 251–267. CrossRef

Gau, S., Chen, S., et al. (2008). National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry, 69(1), 131–140. PubMedCrossRef

Gau, S., Shen, H., et al. (2006). Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Journal of Child & Adolescent Psychopharmacology, 16, 286–297. CrossRef

George, J., Phun, Y. T., et al. (2004). Development and validation of the Medication Regimen Complexity Index. The Annals of Pharmacotherapy, 38(9), 1369–1376. PubMedCrossRef

Giarelli, E., Wiggins, L., Rice, C. E., Levy, S. E., Kirby, R. S., Pinto-Martin, J., et al. (2010). Sex differences in the evaluation and diagnosis of autism spectrum disorders among children. Disability and Health Journal, 3(2), 107–116. PubMedCrossRef

Gupta, K., & Horne, R. (2001). The influence of health beliefs on the presentation and consultation outcome in patients with chemical sensitivities. Journal of Psychosomatic Research, 50, 131–137. PubMedCrossRef

Hack, S., & Chow, B. (2001). Pediatric psychotropic medication compliance: A literature review and research-based suggestions for improving treatment compliance. Journal of Child and Adolescent Psychopharmacology, 11(1), 59–67. PubMedCrossRef

Hamrin, V., McCarthy, E., et al. (2010). Pediatric psychotropic medication initiation and adherence: A literature review based on social exchange theory. Journal of Child and Adolescent Psychiatric Nursing, 23(3), 151–172. PubMedCrossRef

Handen, B., Johnson, C., et al. (2011). Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures. Journal of Child and Adolescent Psychopharmacology, 21(1), 43–50. PubMedPubMedCentralCrossRef

Hansen, R., Chen, S., et al. (2010). Relationship of pharmaceutical promotion to antidepressant switching and adherence: A retrospective cohort study. Psychiatric Services, 61(12), 1232–1238. PubMedCrossRef

Hastie, T., Tibshirani, R., et al. (2009). The elements of statistical learning: Data mining, inference, and prediction (2nd ed.). New York: Springer.

Horne, R., Hankins, M., et al. (2001). The satisfaction with information about medicines scale (SIMS): A new measurement tool for audit and research. Quality in Health Care, 10, 135–140. PubMedPubMedCentralCrossRef

Horne, R., & Weinman, J. (1999). Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research, 47, 555–567. PubMedCrossRef

Hudson, J., Miller, G., et al. (2007). Explaining racial and ethnic differences in children’s use of stimulant medications. Medical Care, 45(11), 1068–1075. PubMedCrossRef

Joshi, G., Petty, C., et al. (2010). The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: A large comparative study of a psychiatrically referred population. Journal of Autism and Developmental Disorders, 40(11), 1361–1370. PubMedCrossRef

Kalkbrenner, A. E., Daniels, J., Chen, J. C., Poole, C., Emch, M., & Morrissey, J. (2010). Perinatal exposure to hazardous air pollutants and autism spectrum disorders at age 8. Epidemiology, 21(5), 631–641. PubMedPubMedCentralCrossRef

Karve, S., Cleves, M., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2008). An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Medical Care, 46(11), 25–33. CrossRef

Karve, S., Cleves, M., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2009a). Good and poor adherence: Optimal cut-point for adherence measures using administrative claims data. Current Medical Research and Opinion, 25(9), 2302–2310. CrossRef

Karve, S., Cleves, M., et al. (2009b). Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health, 12(6), 989–995. PubMedCrossRef

Kelley, S. O. (1988). Measurement of the complexity of medication regimens of the elderly. University of Missouri-Columbia. pp. 23–58.

King, L., Nicholas, J., et al. (2008). Characteristics of autism spectrum disorders over time, surveillance results from children born between 1992 and 2002. AEP, 18(9), 724–725.

Lazaratou, H., Anagnostopoulos, D., et al. (2007). Parental attitudes and opinions on the use of psychotropic medication in mental disorders of childhood. Annals of General Psychiatry, 6(32). doi: 10.1186/1744-859X-6-32.

Leslie, R. S. (2008). Calculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. http://www.wuss.org/proceedings08/08WUSS%20Proceedings/papers/anl/anl09.pdf. Accessed September 03, 2013.

Leslie, R. S., Gwadry-Sridhar, F., et al. (2008). Calculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. Pharmaceutical Programming, 1(1), 13–19. CrossRef

Levy, S., Giarelli, E., et al. (2010). Autism spectrum disorder and co-occurring developmental, psychiatric, medical conditions among children in multiple populations of the United States. Journal of Developmental and Behavioral Pediatrics, 31, 267–275.

Logan, S., Nicholas, J., et al. (2012). High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Annals of Epidemiology, 22(1), 1–8. PubMedPubMedCentralCrossRef

Mandell, D. S., Morales, K. H., et al. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–e448. PubMedPubMedCentralCrossRef

Mandell, D., Wiggins, L., Carpenter, L., Daniels, J., DiGuiseppi, C., Durkin, M., et al. (2009). Racial/ethnic disparities in the identification of children with autism spectrum disorders. American Journal of Public Health, 99(3), 493–498. PubMedPubMedCentralCrossRef

Marcus, S. (2011). Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50(5), 480–489.

Martin, B., Wiley-Exley, E., et al. (2009). Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Annals of Pharmacotherapy, 43(1), 36–44. PubMedCrossRef

Martin, S., Wolters, P., Calabrese, S. K., Toledo-Tamula, M. A., Wood, L. V., Roby, G., et al. (2007). The antiretroviral regimen complexity index: A novel method of quantifying regimen complexity. Journal of Acquired Immune Deficiency Syndromes, 15(45), 535–544. CrossRef

Matson, J. L., & Nebel-Schwalm, M. S. (2007). Comorbid psychopathology with autism spectrum disorder in children: An overview. Research in Developmental Disabilities, 28(4), 341–352. PubMedCrossRef

McPheeter, M., Warren, Z., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(4), e1312–e1321. CrossRef

Meltzer, H. Y., Lindenmayer, J. P., Kwentus, J., Share, D. B., Johnson, R., & Jayathilake, K. (2014). A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia. Schizophrenia Research, 154(1–3), 14–22. doi: 10.1016/j.schres.2014.02.15.

Ming, X., Brimacombe, M., et al. (2008). Autism spectrum disorders: Concurrent clinical disorders. Journal of Child Neurology, 23(1), 6–13.

Mire, S., Nowell, K., Kubiszyn, T., & Goin-Kochel, R. (2013). Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related? Autism, 18(3). doi: 10.1177/1362361313498518.

Mitchell, W., Scheeier, L., et al. (2000). Adherence to treatment in children with epilepsy: Who follows “doctor’s orders?”. Epilepsia, 41(12), 616–625.

Moore, T., & Symons, F. (2009). Adherence to behavioral and medical treatment recommendations by parents of children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39(8), 1173–1184. PubMedCrossRef

Muir, A., Sanders, L., Wilkinson, W., & Schmader, K. (2001). Reducing medication regimen complexity: A controlled trial. Journal of General Internal Medicine, 16(2), 77–82. PubMedPubMedCentralCrossRef

Myers, S. M. (2007). The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy, 8(11), 1579–1603. PubMedCrossRef

Myers, S. M., Johnson, C. P., et al. (2007). Management of children with autism spectrum disorders. Pediatrics, 120(5), 1162–1182. PubMedCrossRef

Nau, D. (2012). The importance of measuring adherence. PQA. https://www.urac.org/consumers/resources/Includes/Nau_Presentation from https://www.urac.org/consumers/resources/Includes/Nau_Presentation.pdf. Accessed September 03, 2013.

NCQA. (2011). Use and continuity of antipsychotic medications for treatment of schizohrenia. http://www.ncqa.org/portals/0/hedisqm/Use%20and%20Continuity%20of%20APs.pdf. Accessed September 03, 2013.

Nicholas, J., Carpenter, L., King, L., Jenner, W., & Charles, J. (2009). Autism spectrum disorders in preschool-aged children: Prevalence and comparison to a school-aged population. Annals of Epidemiology, 19(11), 808–814. PubMedCrossRef

Nicholas, J., Carpenter, L., et al. (2012). Completeness of case ascertainment for surveillance of autism spectrum disorders using the autism developmental disabilities monitoring network methodology. Disability and Health Journal, 5(3), 185–189. PubMedPubMedCentralCrossRef

Nicholas, J., Charles, J., Carpenter, L., King, L., Jenner, W., & Spratt, E. (2008). Prevalence and characteristics of children with autism-spectrum disorders. Annals of Epidemiology, 18(2), 130–136. PubMedCrossRef

Nicolson, R., Craven-Thuss, B., et al. (2006). A prospective, open-label trial of galantamine in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 621–629. PubMedCrossRef

OARC. (2012). Analysis report: The global landscape of autism research. Office of Autism Research Coordination (OARC). National Institute of Mental Health. Thomas Reuters, Interagency Autism Coordinating Committee (IACC).

Olaniyan, O., dosReis, R., et al. (2007). Community perspectives of childhood behavioral problems and ADHD among African American parents. Ambulatory Pragmatics, 7(3), 226–231.

Oswald, D. P., & Sonenklar, N. A. (2007). Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 17(3), 348–355. PubMedCrossRef

Patel, N., DelBello, M., et al. (2005). Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 16(6), 938–946. CrossRef

Petrie, K., & Wessely, S. (2002). Modern worries, new technology, and medicine. British Medical Journal, 324, 690–691. PubMedPubMedCentralCrossRef

Pinborough-Zimmerman, J., Bilder, D., Satterfield, R., Hossain, S., & McMahon, W. (2009). The impact of surveillance method and record source on autism prevalence: Collaboration with utah maternal and child health programs. Maternal and Child Health Journal, 14(3), 392–400. PubMedCrossRef

Powell, K. C., Van Naarden Braun, K., Singh, R. H., Shapira, S. K., Olney, R. S., & Yeargin-Allsopp, M. (2010). Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism. Pediatrics, 156, 420–426. CrossRef

Radigan, M., Lannon, P., et al. (2005). Medication patterns for attention deficit hyperactivity disorder and comorbid psychiatric conditions in a low-income population. Journal of Child and Adolescent Psychopharmacology, 15(1), 44–56. PubMedCrossRef

Rice, C., Nicholas, J., et al. (2010). Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disability and Health Journal, 3(3), 186–201. PubMedCrossRef

Richardson, L. P., DiGiuseppe, D., et al. (2004). Quality of care for Medicaid-covered youth treated with antidepressant therapy. Archives of General Psychiatry, 61(5), 475–480. PubMedCrossRef

Safer, D. J., Zito, J. M., et al. (2004). Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths. Psychiatric Services, 55(9), 1049–1051. PubMedCrossRef

Schatzberg, A., Cole, J., et al. (2010). Manual of clinical psychopharmacology. Arlington, VA: American Psychiatric Publishing.

Shah, N. (2011). Feds threaten S.C. with $111 million cut to special ed. Education Week. http://blogs.edweek.org/edweek/speced/2011/06/another_state_denied_power_to.html. Accessed September 03, 2013.

Shattuck, P. T., Durkin, M., et al. (2009). Timing of identification among children with an autism spectrum disorder: Findings from a population-based surveillance study. Journal of the American Academy of Child and Adolescent Psychiatry, 48(5), 474–483. PubMedPubMedCentralCrossRef

Simonoff, E., Pickles, A., et al. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47(8), 921–929. PubMedCrossRef

Sleath, B., Domino, M., et al. (2010). Antidepressant and antipsychotic use and adherence among Medicaid-youths: Differences by race. Community Mental Health Journal, 46(3), 265–272. PubMedCrossRef

Stone, V., Hogan, J., et al. (2001). Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: Survey of women in the HER study. JAIDS, 28(2), 124–131. PubMed

Taylor, J., Dove, D., et al. (2012). Interventions for adolescents and young adults with autism spectrum disorders. A. f. H. R. a. Qualtiy. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 12-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. August 2012. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed September 03, 2013.

Thompson, C., et al. (2000). Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic antidepressant. American Journal of Psychiatry, 157, 338–343. PubMedCrossRef

Tylee, A. (2007). Onset of action of antidepressants. British Medical Journal, 334(7600), 911–912. PubMedPubMedCentralCrossRef

Van Narden Braun, K., et al. (2008). Relationships between multiple births and autism spectrum disorders, cerebral palsy, and intellectual disabilities: Autism and developmental disabilities monitoring (ADDM) network—2002 surveillance year. Autism Research, 1(5), 265–316. CrossRef

Visser, S. N., Lesesne, C. A., et al. (2007). National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics, 119(Supplement 1), S99–S106. PubMedCrossRef

Volkmar, F., & Wiesner, L. (2009). A practical guide to autism: What every parent, family member and teacher needs to know (pp. 458–459). Hoboken, NJ: Wiley.

Warren, Z., Veenstra-VanderWeele, J., et al. (2011). Therapies for children with autism spectrum disorders. Comparative effectiveness reviews (No. 26), Rockville (MD): Agency for Healthcare Research and Quality (US). http://www.ncbi.nlm.nih.gov/books/NBK56343/.

Webb, S. (2010). Drugmakers dance with autism. Nature Biotechnology, 28, 772–774. PubMedCrossRef

WHO. (2003). Adherence to long-term therapies—Evidence for action. WHO Library Cataloguing-inPublication Data. http://apps.who.int/medicinedocs/en/d/Js4883e/. Accessed September 03, 2013.

WHO. (2005). Improving access and use of psychotropic medicines. Mental health policy and service guidance package (pp. 8–10). Geneva: WHO. http://www.imhcn.org/wpcontent/uploads/2014/04/improving_access_final_10_01_05.pdf.

WHO and Macroeconomics and Health: Investing in Health for Economic Development. (2001). Report of the Commission on Macroeconomics and Health (pp. 8–83). Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2001/924154550x.pdf.

Wiggins, L. D., Rice, C., & Baio, J. (2009). Developmental regression in children with an autism spectrum disorder identified by a population-based surveillance system. Autism, 13(4), 357–374. PubMedCrossRef

Williams, A., Manias, E., et al. (2008). Interventions to improve medication adherence in people with multiple chronic conditions: A systematic review. Journal of Advanced Nursing, 63(2), 132–143. PubMedCrossRef

Wink, L., & Erickson, C. (2010). Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treatment Options in Neurology, 12, 529–538. PubMedCrossRef

Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., & Murphy, C. (2003). Prevalence of autism in a US metropolitan area. JAMA, 289(1), 49–55. PubMedCrossRef

Yeargin-Allsopp, M., Van Naarden Braun, K., Doernberg, N. S., Benedict, R. E., Kirby, R. S., & Durkin, M. S. (2008). Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: A multisite collaboration. Pediatrics, 121(3), 547–554. PubMedCrossRef

Zito, J. M., Safer, D. J., Sai, D., Gardner, J. F., Thomas, D., Coombes, P., et al. (2008). Psychotropic medication patterns among youth in foster care. Pediatrics, 121(1), e157–e163. PubMedCrossRef

Titel: Rates and Predictors of Adherence to Psychotropic Medications in Children with Autism Spectrum Disorders
Auteurs: Sarah L. Logan
Laura Carpenter
R. Scott Leslie
Kelly S. Hunt
Elizabeth Garrett-Mayer
Jane Charles
Joyce S. Nicholas
Publicatiedatum: 01-11-2014
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 11/2014
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-014-2156-0

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 11/2014

Editorial: ASD and Illegal Behaviors

Traditional and Atypical Presentations of Anxiety in Youth with Autism Spectrum Disorder

Are We Under-Estimating the Association Between Autism Symptoms?: The Importance of Considering Simultaneous Selection When Using Samples of Individuals Who Meet Diagnostic Criteria for an Autism Spectrum Disorder

Associations Between Conceptual Reasoning, Problem Solving, and Adaptive Ability in High-functioning Autism

Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder

White Matter Microstructure Predicts Autistic Traits in Attention-Deficit/Hyperactivity Disorder